EUVIMEDExplore EUVIMED
CrossrefInfo card

Activation of Natural Killer Cells in Patients with Chronic Bone and Joint Infection due to Staphylococci Expressing or Not the Small Colony Variant Phenotype

Sébastien Viel, Paul Rouzaire, Frédéric Laurent, Thierry Walzer, Jacques Bienvenu, Florent Valour, Christian Chidiac, Tristan Ferry, The Lyon BJI Study Group

International Journal of Chronic Diseases · 2014

DOI: 10.1155/2014/280653 ↗
AbstractBibliographic details

Abstract

Chronic bone and joint infections (BJI) are devastating diseases. Relapses are frequently observed, as some pathogens, especially staphylococci, can persist intracellularly by expressing a particular phenotype called small colony variant (SCV). As natural killer (NK) cells are lymphocytes specialized in the killing of host cells infected by intracellular pathogens, we studied NK cells of patients with chronic BJI due to staphylococci expressing or not SCVs (10 patients in both groups). Controls were patients infected with other bacteria without detectable expression of SCVs, and healthy volunteers. NK cell phenotype was evaluated from PBMCs by flow cytometry. Degranulation capacity was evaluated after stimulation with K562 cells in vitro . We found that NK cells were activated in terms of CD69 expression, loss of CD16 and perforin, in all infected patients in comparison with healthy volunteers, independently of the SCV phenotype. Peripheral NK cells in patients with chronic BJI display signs of recent activation and degranulation in vivo in response to CD16-mediated signals, regardless of the type of bacteria involved. This could involve a universal capacity of isolates responsible for chronic BJI to produce undetectable SCVs in vivo , which might be a target of future intervention.

Knowledge that fits your work.

From a free start through personal literature research to the complete Research Suite.

View plans →

Are all publisher full texts included?

No. Bibliographic records, abstracts and full texts are different content types. Full-text availability depends on the source, open access and your existing licences. An EUVIMED plan does not replace additional publisher rights.

View plans →